GlassScriptPhysician profile
Maria A Slack
NPI 1831325661
$931.61
in general payments reported to CMS, 2019-2025
9 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2021: $14.33 · 2022: $20.73 · 2023: $55.29 · 2024: $203 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $247.07 | 2021-2025 | Nucala, Trelegy Ellipta |
| Shire North American Group INC | $205.77 | 2019 | |
| Genentech USA, INC. | $143.36 | 2024-2025 | Xolair |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Ars Pharmaceuticals Operations, INC. | $103.15 | 2025 | Neffy |
| E.R. Squibb & Sons, L.L.C. | $38.40 | 2023 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2019 | |
| Pfizer INC. | $16.89 | 2023 | |
| Novo Nordisk INC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Slack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.